Sign in

    Mark Aleynick

    Biotechnology Equity Analyst at Goldman Sachs

    Mark Aleynick is a Biotechnology Equity Analyst at Goldman Sachs, specializing in research and analysis within the biotechnology sector. At Goldman Sachs, he provides coverage of companies in the biotech industry, delivering insights and investment recommendations to institutional clients. While specific performance metrics and a detailed history of companies covered are not publicly available, his role places him alongside senior analysts in equity research, contributing to sector outlooks and investment theses. Information about prior positions, professional credentials, and industry recognition has not been verified from available sources.

    Mark Aleynick's questions to Allogene Therapeutics (ALLO) leadership

    Mark Aleynick's questions to Allogene Therapeutics (ALLO) leadership • Q2 2025

    Question

    Mark Aleynick, on behalf of Salveen Richter at Goldman Sachs, asked for an update on enrollment progress for the ALPHA-three trial and whether discontinuing the enhanced lymphodepletion (FCA) arm has affected enrollment.

    Answer

    EVP of R&D and CMO Dr. Zachary Roberts reported that enrollment momentum continues. While it's too early to quantify the impact of the protocol change, he noted that early feedback from investigators has been positive, as the simplified standard FC regimen is more familiar and easier to discuss with patients.

    Ask Fintool Equity Research AI

    Mark Aleynick's questions to Intellia Therapeutics (NTLA) leadership

    Mark Aleynick's questions to Intellia Therapeutics (NTLA) leadership • Q2 2025

    Question

    On behalf of Salveen Richter at Goldman Sachs, Mark Aleynick asked for Intellia's perspective on the competitive landscape for Nexi, especially given strong results from a competing RNAi therapy, and its commercial positioning.

    Answer

    President and CEO John Leonard positioned Nexi to be a "very formidable competitor" to any agent in the space. He views positive results from others as confirmation of a large, growing, and significantly underdiagnosed market, particularly the wild-type ATTR-CM population, which constitutes about 90% of cases. He expressed confidence in Intellia's ability to compete aggressively for this large patient pool.

    Ask Fintool Equity Research AI

    Mark Aleynick's questions to AMICUS THERAPEUTICS (FOLD) leadership

    Mark Aleynick's questions to AMICUS THERAPEUTICS (FOLD) leadership • Q2 2025

    Question

    Mark Aleynick of Goldman Sachs asked about the DMX200 program, seeking clarity on the expected timeline for Phase 3 data, the bar for success, and what would be considered a clinically relevant outcome in FSGS.

    Answer

    Chief Development Officer Dr. Jeff Castelli projected that top-line two-year data from the Phase 3 ACTION-3 study would be available in 2027, following expected full enrollment by the end of 2025. He explained the study is powered to show small changes in proteinuria, and that clinical relevance will be demonstrated through responder analyses, specifically the proportion of patients achieving key proteinuria thresholds associated with improved long-term renal outcomes.

    Ask Fintool Equity Research AI